

Thursday, June 13, 2013

UOBKH Highlights

Hartalega (HART MK/SELL/RM6.30/Target: RM4.57)

NGC Project Finally Kicks Off

What's New: Hartalega is buying a 120ha land site from Kumpulan Tanjung Balai Sdn Bhd for RM97m, funded by internal funds and bank borrowings. We understand the land is for its RM1.9b Next Generation Integrated Glove Manufacturing Complex (NGC), which will see its production glove capacity rise by 28.4b pieces annually upon completion in two phases over four years. (Source: Bursa Malaysia)

- i) First phase (2013-17) Targets to add 16.5b pieces of gloves p.a. via 42 interchangeable production lines.
- ii) Second phase (2018-21) Expect another additional 12b pieces of gloves p.a. via 30 interchangeable production lines.

Comments: The delay in the NGC plant which was initially slated to commence operation in 1H13 is well within our and street's expectations. We understand the land purchase is conditional upon the cost of land-filling to be borne by the seller. We reckon the construction of the NGC to kick off in early-4Q13 once the land is filled. We expect the first eight production lines to be commissioned by FY15, which will raise its current production capacity of 13b pieces of gloves p.a. by 24.2% in FY15. Some of the new findings on the NGC plant include:

- *i)* Higher capex. The earlier estimated capex of RM1.5b is now revised to RM1.7b-1.9b due to slightly higher land cost and the cost of setting up the plant.
- *ii)* Increase production capacity. The NGC will now house seven production plants with 72 interchangeable production lines, running at 45,000 pcs of gloves/line/hour (previous plan of seven production plants with 70 interchangeable production lines, running at 40,000 pcs of gloves/line/hour).

Recommendation: Maintain SELL and target price of RM4.57, based on 13x 2014F PE. We foresee a rather aggressive industry capacity expansion within the nitrile glove segment towards 4Q13. Thus, we think the average selling price (ASP) for nitrile gloves will fall, possibly suppressing Hartalega's EBIT margins to 28.0% in FY14 and 26.8% in FY15 (FY13: 29.7%).



Thursday, June 13, 2013

We have based this document on information obtained from sources we believe to be reliable, but we do not make any representation or warranty nor accept any responsibility or liability as to its accuracy, completeness or correctness. Expressions of opinion contained herein are those of UOB Kay Hian Research Pte Ltd only and are subject to change without notice. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of the addressee only and is not to be taken as substitution for the exercise of judgement by the addressee. This document is not and should not be construed as an offer or a solicitation of an offer to purchase or subscribe or sell any securities. UOB Kay Hian and its affiliates, their Directors, officers and/or employees may own or have positions in any securities mentioned herein or any securities related thereto and may from time to time add to or dispose of any such securities. UOB Kay Hian and its affiliates may act as market maker or have assumed an underwriting position in the securities of companies discussed herein (or investments related thereto) and may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies.

UOB Kay Hian (U.K.) Limited, a UOB Kay Hian subsidiary which distributes UOB Kay Hian research for only institutional clients, is an authorised person in the meaning of the Financial Services and Markets Act 2000 and is regulated by Financial Services Authority (FSA).

In the United States of America, this research report is being distributed by UOB Kay Hian (U.S.) Inc ("UOBKHUS") which accepts responsibility for the contents. UOBKHUS is a broker-dealer registered with the U.S. Securities and Exchange Commission and is an affiliate company of UOBKH. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact UOBKHUS, not its affiliate. The information herein has been obtained from, and any opinions herein are based upon sources believed reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All opinions and estimates herein reflect our judgement on the date of this report and are subject to change without notice. This report is not intended to be an offer, or the solicitation of any offer, to buy or sell the securities referred to herein. From time to time, the firm preparing this report or its affiliates or the principals or employees of such firm or its affiliates may have a position in the securities referred to herein or hold options, warrants or rights with respect thereto or other securities of such issuers and may make a market or otherwise act as principal In transactions in any of these securities. Any such non-U.S. persons may have purchased securities referred to herein for their own account in advance of release of this report. Further information on the securities referred to herein may be obtained from UOBKHUS upon request.

UOB Kay Hian (Malaysia) Holdings Sdn Bhd (210102-T)

Suite 19-01/02 19th Floor, Menara Keck Seng, 203 Jalan Bukit Bintang, 55100 Kuala Lumpur, Malaysia. Tel: (603) 2143 1180, Fax: (603) 2143 0298

http://research.uobkayhian.com